The HIV-1 envelope glycoprotein (Env) is essential for viral entry and infection of host cells.Composed of the trimer of the gp120/gp41 heterodimeric glycoproteins, the Env trimer is the primary target for neutralizing antibodies.Extensive research over the past forty years has focused on developing advanced immunogens, specifically recombinant, native-like Env trimers and structure-guided, germline-targeting constructs, to elicit protective antibody responses.The Env trimer is encased by up to 90 N-linked glycosylation sites, whose occupancy effectively shields the underlying protein from immune surveillance.While it is well established that glycosylation of HIV-1 gp120 affects antibody responses in infected individuals and that many broadly neutralizing antibodies (bnAbs) depend on glycan-specific epitopes, the capacity of Env-derived glycopeptides to act as unconventional CD4 T cell epitopes and shape helper T cell responses J o u r n a l P r e -p r o o f remains comparatively underexplored.This review examines the adaptive immune responses triggered by HIV Env, with an emphasis on how Env glycosylation simultaneously constrains B cell recognition and contributes to antigen processing and T cell-mediated immune responses, aiming to lay the groundwork for future vaccine development and to inform strategies that elicit robust and lasting protection against HIV-1 infection.
Niyas et al. (Sun,) studied this question.